89Sr-Radiopharmaceutical
89Sr-Radiopharmaceuticals are strontium-89 based treatments specifically designed to alleviate pain from metastatic bone cancer by precisely targeting tumor sites with beta radiation. Alfa Cytology offers comprehensive 89Sr radiopharmaceutical development services, encompassing targeted molecular design, dosage form optimization, and preclinical evaluation, all aimed at enhancing the therapeutic efficacy for metastatic bone tumors.
Introduction to 89Sr-Radiopharmaceutical
89Sr-Radiopharmaceutical (strontium-89 radiopharmaceutical) is a highly targeted therapeutic drug utilizing the radioisotope 89Sr, which is commonly used to effectively treat pain resulting from cancerous bone metastases. Due to its calcium-like chemical properties, 89Sr is preferentially absorbed into bones, particularly targeting sites of tumor metastasis. Once administered, it emits potent beta particle radiation within the bone, effectively killing tumor cells and significantly alleviating pain and other symptoms associated with bone metastases.
Our Services
Alfa Cytology's 89Sr radiopharmaceutical development service offers innovative radiotherapy solutions for oncology, utilizing strontium-89, a beta-emitting radioisotope, to precisely locate and target cancer cells. Our comprehensive service encompasses the entire process, from drug design and radiolabeling to preclinical testing, with the goal of enhancing therapeutic efficacy while minimizing damage to healthy tissues.
Molecules Conjugated with 89Sr
89Sr radiopharmaceuticals can effectively target bone tissue or other specific sites by binding to various drug types, including small molecules, antibodies, ligands, and peptides for enhanced targeting.
Small Molecule Drugs
Alfa Cytology employs phosphate-like and calcium salt compounds to bind strontium-89, facilitating its accumulation in bone tissue and effectively targeting bone metastases to reduce cancer-related pain and improve patient outcomes significantly.
Antibodies
By attaching 89Sr to monoclonal antibodies or antibody-drug conjugates, Alfa Cytology can precisely target and destroy cancer cells, such as those from prostate cancer metastasized to bone, enhancing treatment specificity and minimizing damage to healthy tissues.
Ligands
In addition to calcium and phosphate salts, small molecule bone-affinity ligands (such as fluoride or certain specific peptides) can also bind to 89Sr. These ligands have a strong affinity for 89Sr and can help 89Sr to accumulate efficiently in bone tissue.
Peptides
Alfa Cytology uses targeting peptides for receptor-mediated delivery of 89Sr, accurately directing the radiopharmaceutical to cancer cells in tumor or inflamed regions, thus providing effective targeted therapy while minimizing impact on adjacent healthy tissues.
Preclinical Services of 89Sr-Radiopharmaceutical
Alfa Cytology not only offers development services for 89Sr-radiopharmaceuticals but also provides comprehensive support for subsequent preclinical studies. With innovative research methodologies and specialized technical teams, Alfa Cytology is committed to delivering high-quality scientific support to our clients and advancing the development process of new drugs.
Physiochemical Evaluation Services
With an exceptional research team and robust R&D capabilities, Alfa Cytology offers not only 89Sr radiopharmaceutical R&D services but also a wide range of nuclide-related solutions, including isotope labeling and custom synthesis. Our expertise extends to optimizing drug delivery and enhancing therapeutic outcomes. If your project faces challenges, please don't hesitate to contact us for expert assistance and innovative solutions tailored to your specific needs.
For research use only. Not intended for any clinical use.
Related Service
